JP2015091235A5 - - Google Patents

Download PDF

Info

Publication number
JP2015091235A5
JP2015091235A5 JP2014237731A JP2014237731A JP2015091235A5 JP 2015091235 A5 JP2015091235 A5 JP 2015091235A5 JP 2014237731 A JP2014237731 A JP 2014237731A JP 2014237731 A JP2014237731 A JP 2014237731A JP 2015091235 A5 JP2015091235 A5 JP 2015091235A5
Authority
JP
Japan
Prior art keywords
polynucleotide
ros fusion
sample
lung cancer
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014237731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015091235A (ja
JP6144247B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015091235A publication Critical patent/JP2015091235A/ja
Publication of JP2015091235A5 publication Critical patent/JP2015091235A5/ja
Application granted granted Critical
Publication of JP6144247B2 publication Critical patent/JP6144247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014237731A 2007-10-18 2014-11-25 ヒト非小細胞肺癌における転座および変異rosキナーゼ Active JP6144247B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99966807P 2007-10-18 2007-10-18
US60/999,668 2007-10-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010529983A Division JP5769968B2 (ja) 2007-10-18 2008-10-20 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017093754A Division JP2017131250A (ja) 2007-10-18 2017-05-10 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Publications (3)

Publication Number Publication Date
JP2015091235A JP2015091235A (ja) 2015-05-14
JP2015091235A5 true JP2015091235A5 (OSRAM) 2015-06-25
JP6144247B2 JP6144247B2 (ja) 2017-06-07

Family

ID=40568038

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010529983A Active JP5769968B2 (ja) 2007-10-18 2008-10-20 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2014237731A Active JP6144247B2 (ja) 2007-10-18 2014-11-25 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2017093754A Pending JP2017131250A (ja) 2007-10-18 2017-05-10 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2019100258A Pending JP2019176862A (ja) 2007-10-18 2019-05-29 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010529983A Active JP5769968B2 (ja) 2007-10-18 2008-10-20 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017093754A Pending JP2017131250A (ja) 2007-10-18 2017-05-10 ヒト非小細胞肺癌における転座および変異rosキナーゼ
JP2019100258A Pending JP2019176862A (ja) 2007-10-18 2019-05-29 ヒト非小細胞肺癌における転座および変異rosキナーゼ

Country Status (8)

Country Link
US (4) US9096855B2 (OSRAM)
EP (3) EP3741851A1 (OSRAM)
JP (4) JP5769968B2 (OSRAM)
AU (4) AU2008314567B2 (OSRAM)
CA (1) CA2702686C (OSRAM)
DK (1) DK2203558T3 (OSRAM)
ES (1) ES2576650T3 (OSRAM)
WO (1) WO2009051846A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP3741851A1 (en) * 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
PL2881402T3 (pl) 2009-02-12 2017-10-31 Cell Signaling Technology Inc Ekspresja zmutowanej ROS w ludzkim raku wątroby
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
JP5861244B2 (ja) 2010-06-22 2016-02-16 公益財団法人がん研究会 新規ros1融合体の検出法
KR20140041906A (ko) 2011-08-02 2014-04-04 화이자 인코포레이티드 암의 치료에 사용하기 위한 크리조티닙
HUE037856T2 (hu) 2012-04-18 2018-09-28 Cell Signaling Technology Inc EGFR és ROS1 rákban
CN105229164B (zh) * 2013-03-15 2019-02-12 爱科谱迅病理研究公司 指示癌症疗法的srm测定
WO2015018918A1 (en) * 2013-08-07 2015-02-12 Universität Zu Köln Novel nrg1 fusion genes in cancer
BR112016024672A2 (pt) 2014-04-25 2021-02-02 Exelixis, Inc método para o tratamento de adenocarcinoma de pulmão
TW202206592A (zh) 2020-04-22 2022-02-16 美商艾歐凡斯生物治療公司 用於協調產製供病患特異性免疫治療之細胞的系統和方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
CA2044593C (en) 1989-11-03 2004-04-20 Kenneth L. Brigham Method of in vivo delivery of functioning foreign genes
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
ES2336444T3 (es) 1990-02-01 2010-04-13 Siemens Healthcare Diagnostics Products Gmbh Obtencion y empleo de ginotecas de anticuerpos humanos ("bancos de anticuerpos humanos").
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE10075010I2 (de) 1990-06-28 2004-01-29 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
AT400722B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante cladosporium herbarum allergene
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6083711A (en) 1996-05-15 2000-07-04 Smithkline Beecham Corporation Proteases compositions capable of binding to said site, and methods of use thereof
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
CA2365625A1 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of substances to cells
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
MA26040A1 (fr) 2001-01-05 2004-04-01 Pfizer Des anticorps pour recepteur i de facteur de croissance insulinique
EP1405070A2 (en) 2001-05-17 2004-04-07 The Public Health Research Institute of the City of New York, Inc. Selection of target sites for antisense attack of rna
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
DE60239962D1 (de) 2001-08-14 2011-06-16 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
EP1427856B1 (en) * 2001-09-18 2011-05-11 Carnegie Institution Of Washington Fusion proteins useful for detecting analytes
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
WO2006116688A2 (en) * 2005-04-26 2006-11-02 Yale University Mif agonists and antagonists and therapeutic uses thereof
DK1973946T3 (da) * 2006-01-20 2015-06-22 Cell Signaling Technology Inc Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
EP2057196B1 (en) 2006-08-25 2010-02-24 Dow Global Technologies Inc. Production of telechelic compounds by metathesis depolymerization
EP3741851A1 (en) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma

Similar Documents

Publication Publication Date Title
JP2015091235A5 (OSRAM)
CN112020562B (zh) 基于crispr效应系统的诊断
CN111108220B (zh) 用于病毒检测的基于crispr效应系统的诊断
JP2019196400A5 (OSRAM)
JP2015156872A5 (OSRAM)
JP2012518421A5 (OSRAM)
JP2017501685A5 (OSRAM)
JP2018117645A5 (OSRAM)
KR20190104030A (ko) Crispr 이펙터 시스템 기반 진단
AU2017258619A1 (en) Sequencing method employing ternary complex destabilization to identify cognate nucleotides
JP2014204730A5 (OSRAM)
JP2017507130A5 (OSRAM)
JP2016195614A5 (OSRAM)
JP2015096066A5 (OSRAM)
JP2016509833A5 (OSRAM)
RU2016112354A (ru) Нуклеиново-кислотный зонд
JP2014530011A5 (OSRAM)
AU2015213570B2 (en) NGS systems control and methods involving the same
RU2471872C1 (ru) Способ дифференциации штаммов yersinia pestis различных подвидов и биоваров методами полимеразной цепной реакции и мультилокусного сиквенс-типирования
US9863009B2 (en) Sequence specific primer pool for multiplex PCR and method of detecting microbial infections in thalassemia patients
CN105255869B (zh) ABCC4基因多态性位点rs3742106的用途及其检测引物与试剂盒
JP2017512204A5 (OSRAM)
CN110225979A (zh) 基于滚环扩增的基因组目标区域富集方法及其应用
JP2011502487A5 (OSRAM)
JP2014168466A5 (OSRAM)